Peripheral neuropathy can affect patients with heart failure, though its prevalence is unknown. After heart transplantation, it can influence the postoperative course and quality of life, but screening for neuromuscular disease is not routinely performed.
Objective:
The aim of this study was to identify the factors associated with neuropathy in a population of patients with heart failure who are candidates for heart transplantation.
Study Design:
Data regarding patients’ clinical history, including recent hospitalizations, were collected. All patients underwent a complete neurological examination and a neurophysiological protocol including nerve conduction studies and concentric needle electromyography.
Results:
Thirty-two patients were included in the study, and neuropathy was diagnosed in 10 (31.3%). Neuropathy was associated with the number of admissions (P = .023; odds ratio [OR]: 1.96) and the total number of days of hospitalization in the year prior to inclusion in the study (P = .010; OR: 1.03). The majority of hospitalizations occurred in the step-down unit (85%), with acute heart failure the leading cause of admission (42%).
Conclusions:
This study shows that neuropathy is frequent in patients with advanced heart failure and that hospitalization for cardiac care, also in the absence of intensive care, is a marker of high risk of neurologic damage. These data can help physicians in selecting and managing candidates for transplantation and can guide decisions on the best immunosuppressive regimen or rehabilitation strategy.
McMurrayJJAdamopoulosSAnkerSD. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):1787–1847. doi:10.1093/eurheartj/ehs104.
2.
DePasqualeECSchweigerMRossHJ. A contemporary review of adult heart transplantation: 2012 to 2013. J Heart Lung Transplant. 2014;33(8):775–784. doi:10.1016/j.healun.2014.04.019.
3.
MehraMRCanterCEHannanMM. The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016; 35(1):1–23. doi:10.1016/j.healun.2015.10.023.
De SezeMPetitHWiartL. Critical illness polyneuropathy. A 2-year follow-up study in 19 severe cases. Eur Neurol. 2000;43(2):61–69.
6.
GavazziAde RinoFBoveriMCPicozziAFranceschiM. Prevalence of peripheral nervous system complications after major heart surgery. Neurol Sci. 20162;37(2):205–209. doi:10/1007/s10072-015-2390-z.
ThieleRIJakobHHundE. Critical illness polyneuropathy: a new iatrogenically induced syndrome after cardiac surgery?Eur J Cardiothorac Surg. 1997;12(6):826–835.
9.
BagnatoSMinàCSant’AngeloA. Occurrence of neuropathies in patients with severe heart failure before and after heart transplantation. Neurol Sci. 2016;37(3):393–401. doi:10.1007/s10072-015-2413-9.
MunozPValerioMPalomoJ. Infectious and non-infectious neurologic complications in heart transplant recipients. Medicine. 2010;89(3):166–175. doi:10.1097/MD.0b013e318dfa59c.
12.
DharR. Neurologic complications of transplantation. Neurocrit Care. 2018;28(1):4–11. doi:10.1007/s12028-017-0387-6.
13.
WatanabeJItoEHatanoMTohyamaTOkadaYTakadaY. Recovery after critical illness polyneuropathy in a patient with orthotopic liver transplantation: a case report. Transplant Proc. 2016;48(9):3207–3209. doi:10.1016/j.transproceed.2016.09.005.
14.
MalheirosSMAlmeidaDRMassaroAR. Neurologic complications after heart transplantation. Arq Neuropsiquiatr. 2002;60(2-A):192–197.
15.
MateenFJvan de BeekDKremersWK. Neuromuscular diseases after cardiac transplantation. J Heart Lung Transplant. 2009;28(3):226–230. doi:10.1016/j.healun.2008.12.004.
16.
DandelMLehmkuhlHBKnosallaCHetzerR. Impact of different long-term maintenance immunosuppressive therapy strategies on patients’ outcome after heart transplantation. Transpl Immunol. 2010;23(3):93–103. doi:10.1016/j.trim2010.04.007.
17.
ShepherdSBatraALernerDP. Review of critical illness myopathy and neuropathy. Neurohospitalist. 2017;7(1):41–48. doi:10.1177/1941874416663729.
18.
RubinosCRulandS. Neurologic complications in the intensive care unit. Curr Neurol Neurosci Rep. 2016;16(6):57. doi:10.1007/s11910-016-0651-8.
19.
ArgovZLatronicoN. Neuromuscular complications in intensive care patients. Handb Clin Neurol. 2014;121:1673–1685. doi:10.1016/B978-0-7020-4088-7-00108-5.
20.
LatronicoN.Critical illness polyneuropathy and myopathy 20 years later. No man’s land? No, it is our land!Intensive Care Med. 2016;42(11):1790–1793.
21.
LatronicoNNattinoGGuarneriBFagoniNAmantiniABertoliniG; GiVITI Study Investigators. Validation of the peroneal nerve test to diagnose critical illness polyneuropathy and myopathy in the intensive care unit: the Multicentre Italian CRIMYNE-2 Diagnostic Accuracy Study. F1000Res. 2014;3:127. doi:10.12688/f1000research.3933.3.
22.
NemesRFülepZLaszloI. Assessment of severity and time course of critical illness neuropathy in septic patients: a prospective observational study. Ideggyogy Sz. 2015;68(1-2):30–36.
23.
SantosPDTeixeiraCSaviA. The critical illness polyneuropathy in septic patients with prolonged weaning from mechanical ventilation: is the diaphragm also affected? A pilot study. Respir Care. 2012;57(10):1594–1601.
24.
ApostolakisEPapakonstantinouNABaikoussisNGPapadopoulosG. Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients. J Anesth. 2015;29(1):112–121. doi:10.1007/s00540-014-1875-x.
25.
HermansGVan den BergheG. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274. doi:10.1186/s13054-015-0993-7.
26.
AxerHGrimmAPorzeliusC. Impairment of small somatic and autonomic nerve fibres in intensive care unit patients with severe sepsis and critical illness polyneuropathy—a single center controlled observational study. BMC Neurol. 2013;13:159. doi:10.1186/1471-2377-13-159.
27.
Dos SantosCCBattJ. ICU-acquired weakness: mechanisms of disability. Curr Opin Crit Care. 2012;18(5):509–517. doi:10.1097/MCC.0b013e328357cb5e.
28.
WilcoxSR. Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: a historical review. J Crit Care. 2017;37:149–155. doi:10.1016/j.jcrc.2016.09.018.
29.
PriceDRMikkelsenMEUmscheidCAArmstrongEJ. Neuromuscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and meta-analysis. Crit Care Med. 2016;44(11):2070–2078.
30.
De LetterMASchmitzPIVisserLH. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2001;29(12):2281–2286.
StollbergerCWinkler-DworakMBlazekGFinstererJ. Association of electrocardiographic abnormalities with cardiac findings and neuromuscular disorders in left ventricular hypertrabeculation/non-compaction. Cardiology. 2007;107(4):374–379.
ColbergSRVinikAI. Exercising with peripheral or autonomic neuropathy: what health care providers and diabetic patients need to know. Phys Sportsmed. 2014;42(1):15–23. doi:10.3810/psm.2014.02.2043.
36.
MehrholzJPohlMKuglerJBurridgeJMückelSElsnerB. Physical rehabilitation for critical illness myopathy and neuropathy. Cochrane Database Syst Rev. 2015;(3):CD010942. doi:10.1002/14651858.CD010942.pub2.
37.
BechsteinWO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–326.
38.
BilbaoIDopazoCCastellsL. Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity. Transplant Proc. 2014;46(9):3104–3107. doi:10.1016/j.transproceed.2014.10.001.
39.
TextorLHHedrickJ. The lived experience of peripheral neuropathy after solid organ transplant. Prog Transplant. 2012;22(3):271–279.
